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The potential for Raman spectroscopy to provide early and improved 
diagnosis on a wide range of tissue and biopsy samples in situ is well 
documented. The standard histopathology diagnostic methods of reviewing 
H&E and/or immunohistochemical (IHC) stained tissue sections provides 
valuable clinical information, but requires both logistics (review, analysis 
and interpretation by an expert) and costly processing and reagents.  
Vibrational spectroscopy offers a complimentary diagnostic tool providing 
specific and multiplexed information relating to molecular structure and 
composition, but is not yet used to a significant extent in a clinical setting. 
One of the challenges for clinical implementation is that each Raman 
spectrometer system will have different characteristics and therefore 
spectra are not readily compatible between systems. This is essential for 
clinical implementation where classification models are used to compare 
measured biochemical or tissue spectra against a library training dataset. 
In this study, we demonstrate the development and validation of a 
classification model to discriminate between adenocarcinoma (AC) and non-
cancerous  intraepithelial metaplasia (IM) oesophageal tissue samples, 
measured on three different Raman instruments across three different 
locations. Spectra were corrected using system transfer spectral correction 
algorithms including wavenumber shift (offset) correction, instrument 
response correction and baseline removal. The results from this study 
indicate that the combined correction methods do minimize the instrument 
and sample quality variations within and between the instrument sites. 
However more tissue samples of varying pathology states and greater tissue 
area coverage (per sample) are needed to properly assess the ability of 
Raman spectroscopy and system transferability algorithms over multiple 
instrument sites. 
Introduction 
Oesophageal cancer is the fifth biggest cancer killer, with rising 
incidence rates
1
. Once patients are found to have symptoms such as 
trouble swallowing the disease is advanced and usually incurable 
(15% of patients survive 5 years
1
). Individuals with a precursor 
condition called Barrett's oesophagus (caused by reflux disease), 
have an increased risk of developing cancer
2,3
. These patients can 
be diagnosed at an early stage using endoscopic surveillance, which 
includes biopsy. Most gastrointestinal cancers occur on the mucosal 
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surface; however dysplastic changes in the oesophagus are invisible 
to the naked eye during endoscopy
4
. Therefore patients with 
Barrett's oesophagus are subjected to routine endoscopy with 
collection of biopsy samples for analysis by histopathology. 
However the gold standard histopathology is not able to accurately 
and reproducibly identify those patients with early disease or those 
who may be harbouring more advanced disease in un-sampled 
areas of the oesophagus
5
; therefore improved and objective 
diagnostic tools are needed
6
.    
Raman spectroscopy (RS) makes use of biochemical or molecular 
analysis of target tissues rather than an individual’s assessment of 
cellular and tissue appearance
7
, therefore RS provides an objective, 
non-destructive, label free, non-invasive, rapid and economical 
method for diagnosis. RS has the potential to be more automated 
and adaptable to routine screening and provides a spectroscopic 
signature of all molecular constituents of the tissue sample, which 
facilitates the analysis and use of subtle molecular changes to 
classify different pathology and tissue states. Due to these 
pathology and tissue-specific spectroscopic signatures, RS has been 
used as a tool in histopathology
8–14
, and cytology
15–18
. It is based on 
inelastic light scattering and occurs when the biological sample is 
illuminated by monochromatic laser light. The interactions between 
the incident photons and molecules in the sample result in 
scattering of the light to produce a characteristic biomolecular 
fingerprint of the sample
19
. 
Kendall et al demonstrated the ability of RS to discriminate 
between 8 pathological groups in oesophageal cancer: normal 
squamous, three subtypes of Barrett’s oesophagus (intestinal 
metaplasia, cardiac and fundic type mucosa), high-grade dysplasia, 
adenocarcinoma, squamous dysplasia and squamous cell carcinoma 
with sensitivities between 73% and 100% and specificities of 90-
100%
8
. Hutchings et al and Shetty et al have demonstrated the 
advanced use of chemometrics (Principal Component Analysis score 
maps) to generate biochemical maps. These maps were used to  
identify cellular constituents associated with malignancy 
20
, and to 
discriminate between different pathology and tissue types
21
.  
 
Development of a miniature confocal fibre optic probe for Raman 
spectroscopic measurements (Day et al 2009
22
) enabled the use of 
fibre optic Raman probe spectral measurements ex-vivo in which 
Almond et al (Almond et al 2012
23
) performed Raman spectroscopic 
measurements on tissue samples from 28 patients using a custom-
built fibre-optic Raman probe, in conjunction with multivariate 
classification models, to differentiate between benign and 
neoplastic oesophageal cancer and pre-cancer. The Raman probe 
system was able to differentiate between normal squamous, 
Barrett’s oesophagus and neoplasia with sensitivities of (83% to 
86%) and specificities of (89% to 99%). In another study by the 
same group (Almond et al 2014
24
), using tissue from 62 patients, 
the authors demonstrated that the Raman probe system, in 
conjunction Principal component fed linear discriminant analysis 
(PC-LDA), was able to achieve a sensitivity of 86% and a specificity 
of 88% for detecting high-grade dysplasia and adenocarcinoma. An 
additional study using a Raman fibre optic probe was conducted by 
Bergholt and co-workers who used, in clinic during endoscopic 
examination, multimodal image-guided Raman endoscopy 
technique for real-time in vivo diagnosis of cancer in the 
oesophagus.
25
 75 oesophageal tissue sites from 27 patients were 
measured and using a LDA diagnostic model was able to achieve an 
accuracy of 96%, sensitivity of 97% and specificity of 95% in the in 
vivo diagnosis of oesophageal cancer.     
There is clearly a clinical need for these types of validated 
multivariate disease-specific classification models, developed to 
classify and discriminate pathology classes. However due to 
instrument artefacts and environmental differences between 
locations (mentioned below), a successful classification model 
constructed using spectra from one instrument system may not 
have the ability to accurately predict spectra measured on another 
second instrument.  
Physical and chemical constitution (e.g. viscosity, particle size, and 
surface texture) of the tissue samples and standards can impact this 
transfer process. The instrument response function can affect signal 
intensity values (these differences/changes could be due to part 
replacement, aging of parts and sources, and gradual change in 
quantum efficiency of the detector over time) and wavenumber 
registration shifts. Ideally these factors can be prevented by pre-
calibrating prior to sample measurement using calibration 
standards. Lastly, instrument environment can affect the validity of 
the classification model on the different instruments. Absolute 
temperature changes, both short and long term, may possibly 
induce instrument changes due to thermal expansion, leading to 
misalignment of optical components and the shifting of spectral 
peaks along the wavelength axis
26
. There are a number of 
standardization methods to attempt to correct the intensity and 
wavenumber shifts including single wavelength standardization 
(SWS), direct standardization (DS) and piecewise direct 
standardization (PDS)
26
. These methods involve determining the 
instrumental differences from a subset of samples measured on the 
primary site instrument and regressing against the same subset 
measured on the secondary site instrument. This determines a 
spectral response that can be used to correct the model differences 
for future measurements. 
The ability to implement models created with data collected on a 
number of machines at various times that can classify data 
measured on different instruments at different sites is critical for 
large scale implementation of Raman spectroscopy in the clinic. In 
this work we investigate the use of calibration standards 
(wavenumber offset correction, instrument response correction 
and baseline fluorescence correction) to develop transferable 
classification models capable of discriminating between 
intraepithelial metaplasia (IM) and adenocarcinoma (AC) 
pathologies in the oesophagus tissue using Raman spectroscopic 
mapping. Stone et al
27
 first attempted system transferability 
between two similar Raman systems (at the same site) by 
determining the energy transfer function of each system from a 
calibrated tungsten-filament lamp and a secondary NPL (National 
Physical Laboratory) standard and then correcting the measured 
oesophageal tissue spectra by multiplying this by the transfer 
function. The authors noted that by calibrating for energy sensitivity 
in each of the systems, there were very few differences in the mean 
tissue spectra between the two systems.  This current study, 
however, is the first paper that has attempted to build a 
classification model, from mapped Raman tissue spectra, and 
validate in three different geographical instrument sites with the 
intention of creating a transferable diagnostic tool suitable for 
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clinical application. Additionally it is the first paper to document the 
use of Raman map spectra (compared to commonly point-
measured spectra) collected from oesophageal tissue samples to 
develop and validate a pathology classification model.    
Materials and methods 
Tissue collection and preparation 
All tissue used in this work was obtained from patients 
undergoing scheduled endoscopy (for Barrett’s surveillance or 
dysplasia) or from patients undergoing surgery for 
oesophageal cancer. These procedures were performed under 
local (endoscopic resection) or general (oesophageal 
resection) anaesthetic in accordance with an approved ethical 
proposal [Gloucestershire Local Research Ethics Committee]. 
At all times the General Medical Council (GMC) Guidelines on 
good clinical practice were followed. 
20 oesophageal samples were collected in total, 10 IM and 10 
AC. Informed written-consent was provided, prior to collection 
of the tissue. Each specimen was placed in a labelled cryovial 
(Thermo Scientific, Waltham, MA, USA) and the specimens 
were immediately snap-frozen in liquid nitrogen, before 
storage at -80°C. 
For every specimen, tissue sections were cut and stained with 
H&E (Haematoxylin and Eosin) and reviewed by a consultant 
histopathologist. Acetate paper on which the specimen was 
mounted in the operating theatre acted not only to orientate 
the sample but also allowed the specimens to adhere to the 
microtome chuck without the need for cutting agents such as 
Optimal Cutting Temperature compound (OCT). 
A freezing microtome was used to obtain a 5-6 micron section 
which was mounted on a plain glass slide for H&E staining, 
while three 8 micron thick tissue sections were mounted on 
three (one for each instrument site) circular 20mm x 1mm 
Raman-grade Calcium Fluoride (CaF2) discs (Crystran, Poole, 
UK) and stored at -80
◦
C in 20mm round coin capsules 
(Leuchtturm, Geesthacht, Germany). Before being used in all 
of the Raman experiments samples were allowed to passively 
thaw at 23
o
C for up to 15 minutes prior to measurement. 
 
Raman spectral tissue measurement  
All three sites (Biophotonics Research Unit, Gloucestershire 
Hospitals NHS Foundation Trust, Gloucester, UK; University of 
Exeter, Exeter, UK; and University College London, London, UK) 
used a Renishaw RA800 series benchtop Raman system 
configured for pathology use; 785nm laser excitation with a 
X50 objective, and motorised XYZ stage.   The system is 
equipped with transmitted and reflected white light imaging 
for sample location. StreamLine™ Raman imaging, a fast 
mapping method, was used for data collection. The spectral 
resolution was 2.5 cm
-1
 with a range of 150-2100 cm
-1
.   The 
Raman spatial resolution is ~1 um.   The system comes with 
fully-automated alignment and calibration routines to ensure 
optimal data reproducibility and transferability. An acquisition 
time of 60s/line was used to collect a 50 × 50 pixel Raman 
image of two selected regions of interest from the tissue 
section (determined by reviewing the H&E slide). 
The spectrometers were regularly calibrated and checked 
using an additional set of external standards including silicon, 
green glass and polystyrene, to automatically calibrate the 
wavenumber axis and to ensure optimal signal.  
 
Data Processing and Analysis 
Streamline™ maps were loaded into Matlab R2014b (The 
Mathworks Inc., Natick, Massachusetts, USA) for data pre-
processing. The spectral range was cropped to the fingerprint 
region (400–1800 cm
-1
). 
 
Three spectral correction transfer methods were applied and 
tested to determine their influences on model classification 
performance: instrument response correction, wavenumber 
offset correction and EMSC fluorescence baseline correction.  
 
Instrument response correction 
Instrument response correction was achieved by comparing 
the ratio of the daily measured and calibrated standard 
spectra from each of the instrument system measured from a 
piece of standardized green glass (three pieces from the same 
source were used, one on each of the three systems) to 
provide an instrument response profile that was then used to 
correct spectra obtained from the tissue specimens. 
 
Wavenumber off-set correction 
Spectra were wavenumber off-set corrected using the 
phenylalanine peak of the average spectrum of each map. 
Peak fitting a pseudo-Voigt profile was used to correct the 
phenylalanine position to 1003cm
-1
.  
 
Extended Multiplicative Scatter correction (EMSC) 
Fluorescence Baseline Correction 
Using Extended Multiplicative Scatter Correction (EMSC), a 
least squares modelling procedure, in a manner already 
described in detail in previous publications
28,29
 including an 
investigation for electronic removal of paraffin peaks from 
infrared spectra
30
. EMSC was used to account for scaling and 
artefacts using a polynomial baseline (3
rd
 order), non-tissue 
measured instrument spectrum for each of the instrument 
systems (measuring without CaF2 substrate or tissue sample 
present) and a representative mean tissue spectrum for each 
instrument spectral dataset. In brief, EMSC is adapted in order 
to neutralize any background (e.g. fluorescence) using a least 
squares modelling procedure. This involves an interference 
matrix introduced into the EMSC algorithm composed of the 
non-tissue instrument spectrum and the mean tissue spectrum 
for each instrument site. This function removes baseline 
fluorescence arising from any tissue fluorophores and 
instrument optics and normalises the dataset to reduce the 
effect of total signal variation (e.g. due to variable focussing 
and thickness of the sample). 
 
Cosmic ray and fluorescence saturation removal 
It is crucial to either remove or replace sharp spikes due to 
cosmic rays and saturated spectra due to fluorescence in order 
to prevent them unduly influencing the data analysis. These 
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artefacts were filtered from the spectral images by applying a 
5 × 5 moving window two-dimensional median filter to each 
wavenumber. For the 5 × 5 window used, the centre pixel was 
replaced with the median value of all pixels in the window for 
the chosen wavenumber.  
 
Principal Component Analysis (PCA)  
Prior to creating and validating a classification model, PCA was 
performed on the complete tissue dataset prior to and after 
implementing the correction algorithms. This determined 
whether the correction methods were able to minimize 
instrument system differences created as a result of different 
instrument environment and instrument response function as 
well as potential sample quality differences.   
PCA reduces the spectral data to a smaller number of 
components that describe the major variations in the dataset, 
in this case instrument, sample quality and pathology 
variations. 
  
Partial Least Squares followed by Discriminant Analysis (PLS-
DA) 
A total of 219,367 individual Raman spectra were collected, 
across all three systems (intraepithelial metaplasia = 114,456; 
adenocarcinoma = 104,911).  
The data matrix was mean centred prior to the application of 
Partial Least Squares Discriminant Analysis (PLS-DA). PLSDA 
reduces the spectral data to a smaller number of components 
that describe the major variations in the dataset, while 
simultaneously correlating the captured variance with the 
consultant pathology classification obtained for each tissue 
sample
31
.  
The number of components used for discriminant analysis was 
determined by increasing the number included until the ability 
of the algorithm to accurately predict the pathology group of 
spectra in the second leave-some-out test dataset no longer 
increased.
31
 
 
Model validation using leave-one-map-out (LOMOCV) cross-
validation 
To fully assess the suitability of Raman spectroscopy for 
distinguishing between the two pathology groups 
(intraepithelial metaplasia and adenocarcinoma) and to test 
the system transferability performance across the three 
instrument sites, the dataset was split 
into training and validation sets by leaving one map out of the 
tissue spectra  
The training dataset was used to generate a statistical model 
and the validation dataset was projected onto the model to 
assess its performance. 
Results and discussion 
In order to assess the ability of the wavenumber offset 
correction (WOC) algorithm on the tissue spectral data and 
whether it will adequately correct for any potential 
wavenumber shift at any of the instrument sites, the polymer 
spectra recorded every day, prior to tissue measurements, was 
analysed prior and post WOC. Figure 1 shows the mean 
spectra of the polymer data calculated from a 5s time-acquired 
50 x 50 pixel map. In figure 1a, it is clear that there is a slight 
shift in the ~1033cm
-1
 peak (and therefore rest of the 
spectrum) between each of the sites. Three polymer peaks 
were initially selected across the fingerprint range and a 2
nd
 
order polynomial correction, including an offset, was applied 
to correct for wavenumber shifts between sites. However, on 
inspection of the polynomial coefficients, it was determined 
that the values were effectively zero for all terms apart from 
the offset. This indicated that it was only necessary to apply an 
offset correction to the tissue data set. For the actual tissue 
dataset, this offset was corrected using the phenylalanine 
1003cm
-1
 tissue peak. Without correction of these slight shifts 
in the tissue dataset, it could negatively affect the ability of our 
algorithm to accurately differentiate between pathology 
groups because the tissue peaks accounting for pathology 
state differences will be masked by these spectral shifts. By 
applying the pseudo-Voigt profile peak-fitting algorithm to the 
data, figure 1b demonstrates that it is possible to correct for 
these spectral shifts and align the spectral data.  
 
Figure 1 – Plot of mean spectra of polymer standard (a) before 
and (b) after corrections for offset wavenumber correction. 
Right panels represent zoom enhanced area of the spectra for 
the 1033cm
-1
 peak 
 
Using WOC in addition to response correction and EMSC on 
the complete tissue data set from each of the instrument sites, 
figure 2 demonstrates the effectiveness of these combined 
correction methods to reduce the variation in the standard 
deviation at all of the sites. Site 1 still seems to show increased 
variation in comparison to the other sites. Although similar 
tissue areas are selected to be measured from the H&E by the 
site 1 user, it is possible that each user at the other two 
instrument sites could be measuring a slightly different area 
from site 1 and therefore could account for the difference in 
the calculated standard deviation.  
 
Figure 2 – Plot of mean spectra of pathologies (by instrument 
site) with 0.5STD before and after offset wavenumber, 
fluorescence baseline correction and normalisation applied 
 
However the combined correction methods (as depicted in the 
flowchart in figure 3) are helping to correct for any sample 
thickness differences as well as variations in baseline, caused 
by fluorophores in tissue and any instrument optical 
fluorescence. In addition the instrument response function is 
corrected by comparing the ratio of the daily green glass 
standard measurement and the calibrated standard spectra to 
decipher the instrument response profile, which is then 
applied to the same day collected map tissue spectra.    
 
Figure 3 – Steps applied of correction and processing of tissue 
data 
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In order to illustrate the impact of the correction methods to 
minimise the instrument site variation within the entire 
dataset, PCA was applied to the mean-centred tissue dataset 
and the first two PCA components are plotted in figure 4. PC1 
and PC2 account for the greatest variance in the tissue data 
independent of any pathology supervision or prior knowledge. 
It is clear in figure 4a, that there is potentially an instrument 
and sample quality variation between and within the 
instrument sites. The individual sites are separating and site 3 
is seems to have 3 clusters of data which could be due to 
either pathology or sample quality differences.  
After applying the correction algorithms in figure 4b which will 
reduce the variation due to sample thickness and quality, 
fluorescence baselines as well as spectral offset and 
instrument transfer function, it is clear that between and 
within the individual instrument sites, that these differences 
are reduced and the data seems to be more tightly clustered. 
However there still appears to be some instrument site 
variation even after the correction has been applied. Due to 
the small sample size (10 adenocarcinoma and 10 
intraepithelial metaplasia tissue samples) as well as small 
region of area actually mapped on each tissue section (two 
50x50 mini-maps at ~1.1µm spatial resolution), we do not 
expect there to be a great variance within the pathology states 
in the existing limited tissue dataset.  Therefore, in this current 
tissue dataset, it is assumed that any instrument and sample 
quality variation would become more prominent. We believe 
that these remaining site variations could be due to two 
different factors: 1) instrument and 2) sampling area.  
Correction for instrument differences (i.e. wavenumber offset 
correction, instrument response and background correction) 
have been applied, therefore the remaining differences seen in 
the figure 4b between the sites could be either due 
deficiencies in the correction methods or remaining 
instrument differences which we have not addressed. For 
example, the signal and noise levels were higher in site 1 (due 
to higher laser power at objective) which would have 
increased both the Raman peak signals from tissue as well the 
instrument noise, enough to separate some of site 1 data from 
site 2 & 3 datasets, and demonstrated in the PC plot. 
Additionally, point spread function (PSF) could also play a part 
in instrument differences as it is already a challenge to 
maintain a constant PSF imaging performance over the full 
detector of one detector, never mind three different detectors 
on the three different systems.  
The second source of difference is possibly due to sampling 
differences between the sites. After further analysis of the PC 
plot, it was discovered that a majority of the data points 
having the most variation were in the IM pathology. After 
checking with the areas selected from each of the tissue 
sections from all the sites, it was concluded that there was a 
small difference in how the IM tissue sampling areas were 
selected between sites 1 and sites 2 & 3. The Barrett's 
epithelium in IM, compared with adenocarcinoma, contains a 
number of tissue features: goblet cells and intervening non-
goblet columnar cells in crypts with irregular, budding and 
distortion. IM areas selected by sites 2 & 3 concentrated 
mostly on dense areas of goblet cells showing dysplasia while 
site 1 selected areas included more tissue feature coverage: 
the goblet cells, non-goblet columnar cells in the crypts as well 
as some of the luminal surface. We believe it is the inclusion of 
a broader region of tissue features at site 1 measurements 
compared to site 2 & 3 that is responsible for the increase in 
data variation. For future measurements, there will be more 
agreement of the sampling area and features being measured. 
These considerations will hopefully help reduce some of the 
variation between the measurements sites.  
 
Figure 4 - Plot of PCA scores of PC1 vs PC2 of mean-centred tri-
centre data to demonstrate the instrument site dependence of 
data and need for correction algorithms. (a) before (b) after 
correction 
 
Table 1 documents the training performance of the site 1 
tissue dataset after applying PLS-DA and the impact of 
applying the correction algorithms. The tissue data from site 1 
was mean centred and then PLS was applied to reduce the 
spectral data to smaller number of components the major 
variation in the dataset relevant to the pathology states. 
Although the correction method improved the resulting 
specificity (99.5% vs 95.9%) in discriminating adenocarcinoma 
from intraepithelial metaplasia, the sensitivity reduced from 
99.5% to 94.7% following correction, which indicates little 
impact on the training performance for a single site. However 
this is not greatly surprising as the dataset is from one 
instrument site and therefore the instrument transfer function 
corrections we applied will have minimal impact compared to 
multi-site analysis.   
 
Table 1 - Table for training performance of PLS-DA on site 1 
before and after correction applied to differentiate 
intraepithelial metaplasia (IM) from adenocarcinoma (AC) 
   
In order to assess some of the spectral differences between 
the two pathology groups of interest (adenocarcinoma and 
intraepithelial metaplasia), the corrected tissue spectra from 
all three instrument sites were combined and the mean 
spectrum for each of the two pathology groups was calculated 
(figure 5). By analysing the spectral differences in these two 
spectra, adenocarcinoma has higher intensities in nucleic acids 
(cytosine and uracil at 783cm
-1
 and 840cm
-1
 O–P–O stretch) 
but reduced protein content (amino acid peaks at 754, 1002, 
1121, 1603-1622cm
-1
, and amide III at 1246cm
-1
). Shetty et al
20
 
documented similar changes and attributed this to cells 
undergoing dysplastic or malignant change in carcinogenesis in 
oesophageal tissue. This observation is also in agreement with 
Stone et al
10
 who observed an increase in nucleic acid content 
in increasing carcinogenesis in laryngeal cancer tissue samples 
using similar peak positions for reference as did Haka et al
32
 in 
breast cancer tissue using Raman spectroscopy. 
 
Figure 5 - Mean spectra for intraepithelial metaplasia (IM) vs 
adenocarcinoma (AC) for all sites 
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Finally, to assess the classification performance of measured 
tissue spectra from all three instrument sites with and without 
correction applied, leave one sample out cross validation 
(LOOCV) and using data from one instrument site as the 
training site (site 1) analysis was performed. Table 2 describes 
the classification performance achieved. Again, although the 
correction methods improved the sensitivity of the 
classification model to differentiate between adenocarcinoma 
and intraepithelial metaplasia (from 86% to 96% when site 2 
was the test set and 73% to 79% when site 3 was the test set) 
the specificity was reduced (from 84% to 77% for site 2 as test 
set and 85% to 81% when site 3 was the test set). This suggests 
that although the correction method improves the 
classification sensitivity of the model (i.e. the ability of the 
model to correctly identify those samples that are 
adenocarcinoma correctly) there is a reduction in the 
specificity (ability of the model to correctly identify those 
samples that are not classified as adenocarcinomas).         
 
Table 2 - Table of classification performance for LOOCV with 
and without all corrections methods applied to differentiate 
intraepithelial metaplasia (IM) from adenocarcinoma (AC) 
 
Overall, the results together indicates that although the 
correction models do minimize the instrument and sample 
quality variations within and between the instrument sites, 
they do not currently improve the overall performance of the 
classification model when taking into account both the 
specificity and sensitivity performance. In order to further 
improve the classification performance of these models, 
potentially further standardisation procedures, calibrations, 
transfer corrections and modelling options need to be 
implemented in order to achieve similar results to the within-
site model. Additionally this classification model was 
constructed from only 20 tissue samples over two pathology 
groups with limited sampling area from each tissue sample.  A 
larger sample collection with more tissue samples of varying 
pathology states and greater tissue area coverage (per sample) 
is needed to properly assess the ability of Raman spectroscopy 
and system transferability algorithms over multiple instrument 
sites in oesophageal cancer diagnostics.  
 
A few studies in the last 20 years have investigated models 
transferability in the field of spectroscopy
33–36
. Myles et al
37
 
published a study on a multivariate classification model 
constructed from near-infrared spectra measured in order to 
discriminate between green Arabica and Robusta coffee 
beans. This model was transferred to a second instrument and 
investigated for classification performance. In order to allow 
this classification model to perform optimally on this second 
system, multiple correction algorithms were investigated 
including: modified version of slope/bias correction (SBC), 
orthogonal signal correction (OSC), and model updating (MU). 
These corrections resulted in misclassification errors in the 
second instrument site between 5-10%. Anibal et al
38
 assessed 
the performance of multivariate calibration transfer methods 
(such as Piecewise Direct Standardization (PDS)) used to 
discriminate between unadulterated samples and samples 
adulterated with four Sudan dyes. These were measured using 
UV-visible spectroscopy by different operators and varying the 
time in which the samples were analysed to represent the 
different experimental parameters/conditions that need 
correcting. By using PDS, the authors were able to determine 
transfer functions and apply them to improve the classification 
performance for the other measurement conditions to yield 
results comparable to the original measurement condition. 
Rodriguez and co-workers
39
 used standardisation models on 
Raman spectra of a set of pharmaceutical chemical samples. 
These chemicals were measured on five-commercially 
available 785nm Raman spectrometers (different laboratory-
based and portable platforms). As part of the standardisation 
process, the authors applied shift correction, intensity 
correction, and resolution matching and interpolation. The 
results indicated that the differences in Raman spectra from 
these chemical standards acquired on different spectrometers 
can be corrected, with satisfactory results, using their 
recommended standardisation protocol. They concluded that 
the most dramatic effects came from correcting for 
instrument-instrument variations in Raman shift axis and 
resolution matching.        
All these previous studies were performed on commercial 
chemicals and food products. Human tissue samples 
measurements are subject to greater variations in sample 
quality, thickness, density, composition and preparation, which 
require a greater level of standardisation and system transfer 
spectral correction algorithms.  
 
A larger study including both oesophageal and colon cancer 
tissue samples using the existing correction algorithms 
documented in this current study as well as a number of 
multivariate calibration transfer methods (such as Piecewise 
Direct Standardization (PDS) model updating (MU)) are 
currently being investigated within our collaboration.  
Of interest to future clinical implementation of Raman 
spectroscopy as is the need to generate a classification model 
from data collected on a number of different machines and to 
then use the system transferability correction algorithms to 
predict pathology samples collected from a completely 
different set of sites and Raman spectroscopy systems. This 
current study used instruments of similar parameter designs 
however the true test of the implementation of this 
technology into clinic and worldwide is being able to 
implement this model on independent machine(s) of different 
design specifications.  This would however require significant 
collaboration between an increased number of institutes, 
much larger sample sizes and more advanced multivariate 
analysis.  
 
Conclusions 
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Raman spectroscopy combined with advanced multivariate 
analysis is able to decipher a wealth of biochemical 
information from tissue samples of different pathology states. 
This information can be used to identify biomarkers associated 
with pre-malignant and carcinogenic change. This is important 
for non-invasive detection of disease as well as its classification 
and grading to help in patient diagnosis and prognosis.  
Streamline™ Raman mapping and imaging in conjunction with 
rapid spectral analysis has significant potential to be able to 
collect more tissue spectra data from tissue samples increasing 
the amount of information available to spectroscopists to 
develop validated classification models. 
In order to implement this technology in clinic and in general 
introduce Raman spectroscopy as a clinical tool for more 
global use in medical diagnostics, classification models 
constructed from spectra from one or more instruments must 
to be transferable between instruments and centres. Studies, 
such as this, help to investigate the potential of these models 
with their system transfer correction algorithms to transfer 
between different Raman spectroscopy systems at 
geographically different locations. There are a number of 
challenges ahead in order to develop the classification and 
optimal system transfer models, however collaborative studies 
such as this introduces the means and foundation for these 
further investigations.     
Acknowledgements 
This work was funded and supported by Innovate UK – 
‘SMART: Stratified Medicine through Advanced Raman 
Technologies’. We thank Renishaw Plc for system support and 
development. The histopathology technicians at 
Gloucestershire Hospitals NHS Trust in Gloucester, especially 
Joanne Motte, have worked extremely hard on additional 
sample processing and preparation. 
References 
1 Cancer Research UK, Cancer Res. UK, 2012. 
2 H. Pohl and H. G. Welch, J. Natl. Cancer Inst., 2005, 97, 
142–146. 
3 J. Lagergren, R. Bergstrom, A. Lindgren and O. Nyren, N 
Engl J Med, 1999, 340, 825–831. 
4 Stephan M. Wildi and Michael B. Wallace, Barrett’s 
Esophagus and Esophageal Adenocarcinoma, John Wiley & 
Sons, 2008. 
5 B. J. Reid, R. C. Haggitt, C. E. Rubin, G. Roth, C. M. Surawicz, 
G. Van Belle, K. Lewin, W. M. Weinstein, D. a Antonioli and 
H. Goldman, Hum. Pathol., 1988, 19, 166–178. 
6 C. L. Booth and K. S. Thompson, J. Gastrointest. Oncol., 
2012, 3, 232–42. 
7 L. M. Almond, J. Hutchings, N. Shepherd, H. Barr, N. Stone 
and C. Kendall, J. Biophotonics, 2011, 4, 685–95. 
8 C. Kendall, N. Stone, N. Shepherd, K. Geboes, B. Warren, R. 
Bennett and H. Barr, J. Pathol., 2003, 200, 602–609. 
9 N. Stone, C. Kendall, N. Shepherd, P. Crow and H. Barr, J. 
Raman Spectrosc., 2002, 33, 564–573. 
10 N. Stone, P. Stavroulaki, C. Kendall, M. Birchall and H. Barr, 
Laryngoscope, 2000, 110, 1756–1763. 
11 P. Crow, N. Stone, C. a Kendall, J. S. Uff, J. a M. Farmer, H. 
Barr and M. P. J. Wright, Br. J. Cancer, 2003, 89, 106–108. 
12 J. Smith, C. Kendall, a Sammon, J. Christie-Brown and N. 
Stone, Technol. Cancer Res. Treat., 2003, 2, 327–32. 
13 R. Kast, G. Auner, S. Yurgelevic, B. Broadbent, A. 
Raghunathan, L. M. Poisson, T. Mikkelsen, M. L. Rosenblum 
and S. N. Kalkanis, J. Neurooncol., 2015, 125, 287–295. 
14 F. M. Lyng, D. Traynor, I. R. M. Ramos, F. Bonnier and H. J. 
Byrne, Anal. Bioanal. Chem., 2015, 407, 8279–8289. 
15 Z. Farhane, F. Bonnier, A. Casey, A. Maguire, L. O’Neill and 
H. J. Byrne, Analyst, 2015, 140, 5908–19. 
16 S. J. Harder, Q. Matthews, M. Isabelle, A. G. Brolo, J. J. Lum 
and A. Jirasek, Appl. Spectrosc., 2015, 69, 193–204. 
17 T. Tolstik, C. Marquardt, C. Matthäus, N. Bergner, C. 
Bielecki, C. Krafft, A. Stallmach and J. Popp, Analyst, 2014, 
139, 6036–43. 
18 Q. Matthews, A. Brolo, J. Lum, X. Duan and a Jirasek, Phys. 
Med. Biol., 2010, 56, 19–38. 
19 C. Kendall, M. Isabelle, F. Bazant-Hegemark, J. Hutchings, L. 
Orr, J. Babrah, R. Baker and N. Stone, Analyst, 2009, 134, 
1029–45. 
20 G. Shetty, C. Kendall, N. Shepherd, N. Stone and H. Barr, Br. 
J. Cancer, 2006, 94, 1460–4. 
21 J. Hutchings, C. Kendall, B. Smith, N. Shepherd, H. Barr and 
N. Stone, J. Biophotonics, 2009, 2, 91–103. 
22 J. C. C. Day, R. Bennett, B. Smith, C. Kendall, J. Hutchings, G. 
M. Meaden, C. Born, S. Yu and N. Stone, Phys. Med. Biol., 
2009, 54, 7077–87. 
23 L. M. Almond, J. Hutchings, C. Kendall, J. C. C. Day, O. A. C. 
Stevens, G. R. Lloyd, N. A. Shepherd, H. Barr and N. Stone, 
J. Biomed. Opt., 2012, 17, 081421–1. 
Page 7 of 13 Faraday Disc sions
Fa
ra
da
y
D
is
cu
ss
io
ns
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
17
 D
ec
em
be
r 2
01
5.
 D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f C
al
ifo
rn
ia
 - 
Sa
n 
D
ie
go
 o
n 
23
/1
2/
20
15
 1
4:
37
:2
1.
 
View Article Online
DOI: 10.1039/C5FD00183H
ARTICLE Faraday Discussions 
8 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx 
Please do not adjust margins 
Please do not adjust margins 
24 L. M. Almond, J. Hutchings, G. Lloyd, H. Barr, N. Shepherd, 
J. Day, O. Stevens, S. Sanders, M. Wadley, N. Stone and C. 
Kendall, Gastrointest. Endosc., 2014, 79, 37–45. 
25 M. S. Bergholt, W. Zheng, K. Lin, K. Y. Ho, M. Teh, K. G. 
Yeoh, J. B. So and Z. Huang, Technol. Cancer Res. Treat., 
2011, 10, 103–12. 
26 D. Ozdemir, M. Mosley and R. Williams, Appl. Spectrosc., 
1998, 52, 1203–1209. 
27 N. Stone, C. Kendall and H. Barr, in Handbook of Vibrational 
Spectroscopy, John Wiley & Sons, Ltd, 2006. 
28 N. K. Afseth and A. Kohler, Chemom. Intell. Lab. Syst., 2012, 
117, 92–99. 
29 H. Martens and E. Stark, J. Pharm. Biomed. Anal., 1991, 9, 
625–635. 
30 J. Nallala, G. R. Lloyd and N. Stone, Analyst, 2015, 140, 
2369–75. 
31 G. R. Lloyd, L. E. Orr, J. Christie-Brown, K. McCarthy, S. 
Rose, M. Thomas and N. Stone, Analyst, 2013, 138, 3900–
3908. 
32 A. S. Haka, K. E. Shafer-Peltier, M. Fitzmaurice, J. Crowe, R. 
R. Dasari and M. S. Feld, Proc. Natl. Acad. Sci. U. S. A., 
2005, 102, 12371–6. 
33 C. K. Mann and T. J. Vickers, Appl. Spectrosc., 1999, 53, 
856–861. 
34 H. Nguyen Quang, M. Jouan and N. Quy Dao, Anal. Chim. 
Acta, 1999, 379, 159–167. 
35 H. Swierenga, A. P. de Weijer, R. J. van Wijk and L. M. C. 
Buydens, Chemom. Intell. Lab. Syst., 1999, 49, 1–17. 
36 H. Swierenga, A. P. de Weijer and L. M. C. Buydens, J. 
Chemom., 1999, 13, 237–249. 
37 A. J. Myles, T. A. Zimmerman and S. D. Brown, Appl. 
Spectrosc., 2006, 60, 1198–203. 
38 C. V Di Anibal, I. Ruisánchez, M. Fernández, R. Forteza, V. 
Cerdà and M. Pilar Callao, Food Chem., 2012, 134, 2326–
31. 
39 J. D. Rodriguez, B. J. Westenberger, L. F. Buhse and J. F. 
Kauffman, Analyst, 2011, 136, 4232–40.  
Page 8 of 13Faraday Discussions
Fa
ra
da
y
D
is
cu
ss
io
ns
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
17
 D
ec
em
be
r 2
01
5.
 D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f C
al
ifo
rn
ia
 - 
Sa
n 
D
ie
go
 o
n 
23
/1
2/
20
15
 1
4:
37
:2
1.
 
View Article Online
DOI: 10.1039/C5FD00183H
(a)  
(b)  
Figure 1 – Plot of mean spectra of polymer standard (a) before and (b) after corrections for offset wavenumber 
correction. Right panels represent zoom enhanced area of the spectra for the 1033cm
-1
 peak 
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 Figure 2 – Plot of mean spectra of pathologies (by instrument site) with ±0.5STD before and after offset 
wavenumber, instrument response correction, and fluorescence baseline correction and normalisation applied 
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 Figure 3 – Steps applied of correction and processing of tissue data  
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 (a)  
(b)  
Figure 4- Plot of PCA scores of PC1 vs PC2 of mean-centred tri-centre data to demonstrate the instrument site 
dependence of data and need for correction algorithms (a) before (b) after 
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 Table 1 – Training performance of PLS-DA on site 1 before and after correction applied to differentiate 
intraepithelial metaplasia (IM) from adenocarcinoma (AC) 
 
Figure 5 - Mean spectra for intraepithelial metaplasia (IM) vs adenocarcinoma (AC) for all sites 
 
Table 2 - Classification performance for LOOCV with and without all corrections methods applied to differentiate 
intraepithelial metaplasia (IM) from adenocarcinoma (AC) 
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